Meeting
2021 ASCO Annual Meeting
Improved survival among patients with malignant pleural mesotheliomas who develop immune-related adverse events on immunotherapy.
Authors
Michael Offin
Memorial Sloan Kettering Cancer Center, New York, NY
Michael Offin , Jacklynn V. Egger , Caroline G. McCarthy , Vasilisa Rudneva , Jason Beattie , Michelle S. Ginsberg , Jennifer L. Sauter , Andreas Rimner , Valerie W. Rusch , Prasad S. Adusumilli , Marjorie Glass Zauderer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8556)
DOI
10.1200/JCO.2021.39.15_suppl.8556
Abstract #
8556
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Association between immune-related adverse events and microbiome composition in patients with advanced non–small cell lung cancer treated with immunotherapy.
First Author: Marion Tonneau
Poster
2022 ASCO Annual Meeting
Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.
First Author: Lyndsey L Prather
Poster
2020 ASCO Virtual Scientific Program
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
First Author: Taiki Hakozaki
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Outcomes with immunotherapy between Lynch syndrome vs non-Lynch syndrome microsatellite instability-high colorectal cancer.
First Author: Cody Eslinger